Results 131 to 140 of about 811,174 (190)
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Remibrutinib as a Therapeutic Option for Solar Urticaria
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares +3 more
wiley +1 more source
Sebastian Torke,1,* Sarah Dybowski,2,* Martin S Weber2– 41Experimental and Clinical Research Center, Charité-Medical Center Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; 2Department of Neurology, University ...
Torke S, Dybowski S, Weber MS
doaj
BTK Inhibitors: Past, Present, and Future
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that are safer but still face challenges of resistance mutations.
Skye Montoya +2 more
exaly +4 more sources
Evolution of BTK inhibitors [PDF]
The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib has demonstrated superior efficacy over traditional chemotherapy in several randomized clinical trials in terms of ...
Mathew, Dena
openaire +2 more sources
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
In the past few years, Bruton’s tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk ...
Chiara Brullo +2 more
exaly +3 more sources
Pirtobrutinib After a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia [PDF]
In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 ...
Chan Yoon Cheah +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Expert Review of Hematology, 2022The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and a multi-disciplinary approach.The increasing indications and addition of newer agents to clinical practice and ...
Bradley W. Christensen +2 more
openaire +2 more sources
On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors
Cancer Discovery, 2022Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire +2 more sources

